Helicos' Q3 Loss Rises 15 Percent, Expects Orders at Low End of Guidance | GenomeWeb
This article has been updated to include additional comments from Helicos' conference call this morning.
 
NEW YORK (GenomeWeb News) – Helicos BioSciences today reported a 15 percent increase in its third-quarter net loss and a dip in grant revenue as it continues to perform validation studies of its flagship Helicos Genetic Analysis Platform in house. It also revised its guidance downward on orders for the system for the remainder of this year, citing economic conditions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.